Purinergic signaling, dyslipidemia and infammatory disease

Cellular Physiology and Biochemistry

Volumn 30, Issue 6, 2012, Pages 1333-1339

  Sparks, Daniel L ^a   Chatterjee, Cynthia ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Autophagy; Infammation; Insulin receptor; Lipoprotein; Nucleotides; Purinergic signaling

Indexed keywords

CD39 ANTIGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN RECEPTOR; LIPOPROTEIN; NUCLEOTIDE; PURINERGIC RECEPTOR; TRIACYLGLYCEROL;

AUTOPHAGY; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATORY DISEASE; INSULIN RESISTANCE; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; METABOLIC DISORDER; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84867671995     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000343322     Document Type: Review

References (62)

1. Von Albertini M, Palmetshofer A, Kaczmarek E, Koziak K, Stroka D, Grey ST, Stuhlmeier KM, Robson SC: Extracellular ATP and ADP activate transcription factor NF-kappa B and induce endothelial cell apoptosis. Biochem Biophys Res Commun 1998;248:822-829. (Pubitemid 28404507)
2. Di Virgilio F, Solini A: P2 receptors: new potential players in atherosclerosis. Br J Pharmacol 2002;135:831-842. (Pubitemid 34214442)
3. Di Virgilio F, Boeynaems JM, Robson SC: Extracellular nucleotides as negative modulators of immunity. Curr Opin Pharmacol 2009;9:507-513.
4. Dwyer KM, Deaglio S, Gao W, Friedman D, Strom TB, Robson SC: CD39 and control of cellular immune responses. Purinergic Signal 2007;3:171-180.
5. Brown PR, Parks RE, Jr., Herod J: Use of high-pressure liquid chromatography for monitoring nucleotide concentration in human blood: a preliminary study with stored blood cell suspensions. Clin Chem 1973;19:919-922.
6. Harkness RA, Coade SB, Webster AD: ATP, ADP and AMP in plasma from peripheral venous blood. Clin Chim Acta 1984;143:91-98. (Pubitemid 15214055)
7. Erlinge D, Burnstock G: P2 receptors in cardiovascular regulation and disease. Purinergic Signal 2008;4:1-20.
8. Trautmann A: Extracellular ATP in the immune system: more than just a "danger signal". Sci Signal 2009;2:e6.
9. Lohman AW, Billaud M, Isakson BE: Mechanisms of ATP release and signalling in the blood vessel wall. Cardiovasc Res 2012;95:269-280.
10. Bours MJ, Dagnelie PC, Giuliani AL, Wesselius A, Di Virgilio F: P2 receptors and extracellular ATP: a novel homeostatic pathway in inflammation. Front Biosci (Schol Ed) 2011;3:1443-1456.
11. Parodi J, Flores C, Aguayo C, Rudolph MI, Casanello P, Sobrevia L: Inhibition of nitrobenzylthioinosinesensitive adenosine transport by elevated D-glucose involves activation of P2Y2 purinoceptors in human umbilical vein endothelial cells. Circ Res 2002;90:570-577. (Pubitemid 34640907)
12. Solini A, Iacobini C, Ricci C, Chiozzi P, Amadio L, Pricci F, Di MU, Di Virgilio F, Pugliese G: Purinergic modulation of mesangial extracellular matrix production: role in diabetic and other glomerular diseases. Kidney Int 2005;67:875-885. (Pubitemid 41623312)
13. Nilsson J, Nilsson LM, Chen YW, Molkentin JD, Erlinge D, Gomez MF: High glucose activates nuclear factor of activated T cells in native vascular smooth muscle. Arterioscler Thromb Vasc Biol 2006;26:794-800. (Pubitemid 43732153)
14. Kukulski F, Levesque SA, Sevigny J: Impact of ectoenzymes on p2 and p1 receptor signaling. Adv Pharmacol 2011;61:263-299.
15. Deaglio S, Robson SC: Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv Pharmacol 2011;61:301-332.
16. Bertrand G, Chapal J, Puech R, Loubatieres-Mariani MM: Adenosine-5'-O-(2-thiodiphosphate) is a potent agonist at P2 purinoceptors mediating insulin secretion from perfused rat pancreas. Br J Pharmacol 1991;102:627-630.
17. Fernandez-Alvarez J, Hillaire-Buys D, Loubatieres-Mariani MM, Gomis R, Petit P: P2 receptor agonists stimulate insulin release from human pancreatic islets. Pancreas 2001;22:69-71. (Pubitemid 32046218)
18. Mistafa O, Hogberg J, Stenius U: Statins and ATP regulate nuclear pAkt via the P2X7 purinergic receptor in epithelial cells. Biochem Biophys Res Commun 2008;365:131-136. (Pubitemid 350102463)
19. Chatterjee C, Sparks DL: Extracellular nucleotides inhibit insulin receptor signaling, stimulate autophagy and control lipoprotein secretion. PLoS ONE 2012;7:e36916.
20. Tan C, Salehi A, Svensson S, Olde B, Erlinge D: ADP receptor P2Y (13) induce apoptosis in pancreatic betacells. Cell Mol Life Sci 2010;67:445-453.
21. Amisten S, Meidute-Abaraviciene S, Tan C, Olde B, Lundquist I, Salehi A, Erlinge D: ADP mediates inhibition of insulin secretion by activation of P2Y13 receptors in mice. Diabetologia 2010;53:1927-1934.
22. Aga M, Watters JJ, Pfeiffer ZA, Wiepz GJ, Sommer JA, Bertics PJ: Evidence for nucleotide receptor modulation of cross talk between MAP kinase and NF-kappa B signaling pathways in murine RAW 264.7 macrophages. Am J Physiol Cell Physiol 2004;286:C923-C930. (Pubitemid 38543821)
23. Khakh BS, North RA: P2X receptors as cell-surface ATP sensors in health and disease. Nature 2006;442:527-532. (Pubitemid 44167906)
24. Sellers MB, Tricoci P, Harrington RA: A new generation of antiplatelet agents. Curr Opin Cardiol 2009;24:307-312.
25. Chinellato A, Ragazzi E: Receptor-mediated pathways of endothelium activity in experimental atherosclerosis. Pharmacol Res 1995;31:163-168.
26. Bailey AL, Campbell CL: Oral antiplatelet therapy for acute coronary syndromes: aspirin, P2Y12 inhibition and thrombin receptor antagonists. Curr Drug Targets 2011;12:1805-1812.
27. Watala C: Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Curr Pharm Des 2005;11:2331-2365. (Pubitemid 40872701)
28. Solini A, Chiozzi P, Morelli A, Passaro A, Fellin R, Di Virgilio F: Defective P2Y purinergic receptor function: A possible novel mechanism for impaired glucose transport. J Cell Physiol 2003;197:435-444. (Pubitemid 37487042)
29. Solini A, Chiozzi P, Morelli A, Adinolfi E, Rizzo R, Baricordi OR, Di Virgilio F: Enhanced P2X7 activity in human fibroblasts from diabetic patients: a possible pathogenetic mechanism for vascular damage in diabetes. Arterioscler Thromb Vasc Biol 2004;24:1240-1245. (Pubitemid 38880015)
30. Garcia-Hernandez MH, Portales-Cervantes L, Cortez-Espinosa N, Vargas-Morales JM, Fritche Salazar JF, Rivera-Lopez E, Rodriguez-Rivera JG, Quezada-Calvillo R, Portales-Perez DP: Expression and function of P2X (7) receptor and CD39/Entpd1 in patients with type 2 diabetes and their association with biochemical parameters. Cell Immunol 2011;269:135-143.
31. Madec S, Rossi C, Chiarugi M, Santini E, Salvati A, Ferrannini E, Solini A: Adipocyte P2X7 receptors expression: a role in modulating inflammatory response in subjects with metabolic syndrome? Atherosclerosis 2011;219:552-558.
32. Friedman DJ, Talbert ME, Bowden DW, Freedman BI, Mukanya Y, Enjyoji K, Robson SC: Functional ENTPD1 polymorphisms in African Americans with diabetes and end-stage renal disease. Diabetes 2009;58:999-1006.
33. Enjyoji K, Kotani K, Thukral C, Blumel B, Sun X, Wu Y, Imai M, Friedman D, Csizmadia E, Bleibel W, Kahn BB, Robson SC: Deletion of cd39/entpd1 results in hepatic insulin resistance. Diabetes 2008;57:2311-2320.
34. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, Champagne E, Pineau T, Georgeaud V, Walker JE, Terce F, Collet X, Perret B, Barbaras R: Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003;421:75-79. (Pubitemid 36077087)
35. Radojkovic C, Genoux A, Pons V, Combes G, De JH, Champagne E, Rolland C, Perret B, Collet X, Terce F, Martinez LO: Stimulation of cell surface F1-ATPase activity by apolipoprotein A-I inhibits endothelial cell apoptosis and promotes proliferation. Arterioscler Thromb Vasc Biol 2009;29:1125-1130.
36. Cavelier C, Ohnsorg PM, Rohrer L, Von EA: The beta-chain of cell surface F (0) F (1) ATPase modulates apoA-I and HDL transcytosis through aortic endothelial cells. Arterioscler Thromb Vasc Biol 2012;32:131-139.
37. Jacquet S, Malaval C, Martinez LO, Sak K, Rolland C, Perez C, Nauze M, Champagne E, Terce F, Gachet C, Perret B, Collet X, Boeynaems JM, Barbaras R: The nucleotide receptor P2Y13 is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis. Cell Mol Life Sci 2005;62:2508-2515. (Pubitemid 41801103)
38. Fabre AC, Vantourout P, Champagne E, Terce F, Rolland C, Perret B, Collet X, Barbaras R, Martinez LO: Cell surface adenylate kinase activity regulates the F (1)-ATPase/P2Y (13)-mediated HDL endocytosis pathway on human hepatocytes. Cell Mol Life Sci 2006;63:2829-2837. (Pubitemid 44913322)
39. Genoux A, Pons V, Radojkovic C, Roux-Dalvai F, Combes G, Rolland C, Malet N, Monsarrat B, Lopez F, Ruidavets JB, Perret B, Martinez LO: Mitochondrial inhibitory factor 1 (IF1) is present in human serum and is positively correlated with HDL-cholesterol. PLoS One 2011;6:e23949.
40. Zhang LH, Kamanna VS, Zhang MC, Kashyap ML: Niacin inhibits surface expression of ATP synthase {beta} chain in HepG2 cells: implications for raising HDL. J Lipid Res 2008;49:1195-1201.
41. Pandey NR, Renwick J, Rabaa S, Misquith A, Kouri L, Twomey E, Sparks DL: An induction in hepatic HDL secretion associated with reduced ATPase expression. Am J Pathol 2009;175:1777-1787.
42. Fisher EA, Zhou MY, Mitchell DM, Wu XJ, Omura S, Wang HX, Goldberg AL, Ginsberg HN: The degradation of apolipoprotein B100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70. J Biol Chem 1997;272:20427-20434. (Pubitemid 27355595)
43. Adeli K, Macri J, Mohammadi A, Kito M, Urade R, Cavallo D: Apolipoprotein B is intracellularly associated with an ER-60 protease homologue in HepG2 cells. J Biol Chem 1997;272:22489-22494. (Pubitemid 27386058)
44. Rutledge AC, Qiu W, Zhang R, Kohen-Avramoglu R, Nemat-Gorgani N, Adeli K: Mechanisms targeting apolipoprotein B100 to proteasomal degradation: evidence that degradation is initiated by BiP binding at the N terminus and the formation of a p97 complex at the C terminus. Arterioscler Thromb Vasc Biol 2009;29:579-585.
45. Ding WX, Ni HM, Gao W, Yoshimori T, Stolz DB, Ron D, Yin XM: Linking of autophagy to ubiquitinproteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol 2007;171:513-524. (Pubitemid 47344684)
46. Wu WK, Wu YC, Yu L, Li ZJ, Sung JJ, Cho CH: Induction of autophagy by proteasome inhibitor is associated with proliferative arrest in colon cancer cells. Biochem Biophys Res Commun 2008;374:258-263.
47. Zhu K, Dunner K, Jr., McConkey DJ: Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene 2010;29:451-462.
48. Wu WK, Cho CH, Lee CW, Wu YC, Yu L, Li ZJ, Wong CC, Li HT, Zhang L, Ren SX, Che CT, Wu K, Fan D, Yu J, Sung JJ: Macroautophagy and ERK phosphorylation counteract the antiproliferative effect of proteasome inhibitor in gastric cancer cells. Autophagy 2010;6:228-238.
49. Kroemer G, Marino G, Levine B: Autophagy and the integrated stress response. Mol Cell 2010;40:280-293.
50. Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-Thompson ZW, Jimenez-Sanchez M, Korolchuk VI, Lichtenberg M, Luo S, Massey DC, Menzies FM, Moreau K, Narayanan U, Renna M, Siddiqi FH, Underwood BR, Winslow AR, Rubinsztein DC: Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev 2010;90:1383-1435.
51. Ranganathan S, Kottke BA: Rapid regulation of apolipoprotein A-I secretion in HepG2 cells by a factor associated with bovine high-density lipoproteins. Biochim Biophys Acta Lipids Lipid Metab 1990;1046:223-228. (Pubitemid 20287768)
52. Ouimet M, Franklin V, Mak E, Liao X, Tabas I, Marcel YL: Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. Cell Metab 2011;13:655-667.
53. Boeynaems JM, Communi D, Gonzalez NS, Robaye B: Overview of the P2 receptors. Semin Thromb Hemost 2005;31:139-149. (Pubitemid 40605189)
54. Malaval C, Laffargue M, Barbaras R, Rolland C, Peres C, Champagne E, Perret B, Terce F, Collet X, Martinez LO: RhoA/ROCK I signalling downstream of the P2Y13 ADP-receptor controls HDL endocytosis in human hepatocytes. Cell Signal 2009;21:120-127.
55. Verfaillie T, Salazar M, Velasco G, Agostinis P: Linking ER Stress to Autophagy: Potential Implications for Cancer Therapy. Int J Cell Biol 2010;2010:930509.
56. Schofl C, Ponczek M, Mader T, Waring M, Benecke H, Von Zur MA, Mix H, Cornberg M, Boker KH, Manns MP, Wagner S: Regulation of cytosolic free calcium concentration by extracellular nucleotides in human hepatocytes. Am J Physiol 1999;276:G164-G172. (Pubitemid 29063613)
57. Li G, Shi Y, Huang H, Zhang Y, Wu K, Luo J, Sun Y, Lu J, Benovic JL, Zhou N: Internalization of the human nicotinic acid receptor GPR109A is regulated by G (i), GRK2, and arrestin3. J Biol Chem 2010;285:22605-22618.
58. Lukasova M, Malaval C, Gille A, Kero J, Offermanns S: Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest 2011;121:1163-1173.
59. Jin FY, Kamanna VS, Kashyap ML: Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells - Implication for reverse cholesterol transport. Arterioscler Tromb Vasc Biol 1997;17:2020-2028. (Pubitemid 28057103)
60. Marena S, Tagliaferro V, Montegrosso G, Pagano A, Scaglione L, Pagano G: Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes. Diabete Metab 1994;20:15-19. (Pubitemid 24232585)
61. Jojima T, Suzuki K, Hirama N, Uchida K, Hattori Y: Glimepiride upregulates eNOS activity and inhibits cytokine-induced NF-kappaB activation through a phosphoinoside 3-kinase-Akt-dependent pathway. Diabetes Obes Metab 2009;11:143-149.
62. Ben S, I, Tanti JF, Bost F: The combination of metformin and 2 deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells. Autophagy 2010;6. [Epub ahead of print].